藥華藥 News Releases

PharmaEssentia Announces Adjustment of Stock Dividend and Cash Dividend Rates

PharmaEssentia announces the adjustment of its stock and cash dividend payout ratios due to changes … · 2026-06-23

PharmaEssentia Announces Resignation of Corporate Director

PharmaEssentia Corporation announces the resignation of Hsu Hsueh-Hsiang, representative of Yuanta C… · 2026-06-23

PharmaEssentia Corporation: Clarification on Media Reports

PharmaEssentia Corporation clarifies that recent financial forecasts reported by the China Times Bus… · 2026-06-18

[PharmaEssentia] Notice of Completion of Patient Enrollment for Phase 3 Trial

PharmaEssentia completed patient enrollment for its Phase 3 trial of P1101 for myelofibrosis. · 2026-06-10

[PharmaEssentia] Announcement of Key Resolutions from the 2026 Annual General Meeting

PharmaEssentia held its 2026 Annual General Meeting on May 28, approving the 2025 profit distributio… · 2026-05-28

[PharmaEssentia] Announcement of Ex-Dividend Date for Cash Dividends

PharmaEssentia has announced the distribution of cash dividends based on the board resolution dated … · 2026-05-28

PharmaEssentia Receives Approval for New Indication for Besremi from Taiwan's Ministry of Health and Welfare

PharmaEssentia announced that its new drug, Besremi, has received approval from Taiwan's Ministry of… · 2026-05-28

【PharmaEssentia】Announcement of Board Approval for Capital Expenditure Budget Adjustment

PharmaEssentia announced on May 28, 2026, an adjustment to its Zhubei plant construction budget. To … · 2026-05-28

[PharmaEssentia] Announcement of Board Resolution on Ex-Rights Date for Stock Dividends

PharmaEssentia has announced the ex-rights date for its stock dividends as July 15, following resolu… · 2026-05-28

[PharmaEssentia] Announcement on the Completion of Registration for Capital Reduction via Cancellation of Restricted Employee Shares

PharmaEssentia announced that it completed the capital reduction registration for the cancellation o… · 2026-05-25

[PharmaEssentia] Correction to the Notes of the Q1 115 Consolidated Financial Report

PharmaEssentia has announced a correction to the notes regarding the property, plant, and equipment … · 2026-05-19

[PharmaEssentia] Important Subsidiary Pan-Tai Medical Products Co., Ltd. Announces Board Resolution Not to Distribute Dividends for 2025

PharmaEssentia announced that its subsidiary, Pan-Tai Medical Products, has resolved not to issue an… · 2026-05-15

[PharmaEssentia] Important Subsidiary Pan-Tai Medical Products Co., Ltd. Announces Board Resolution Not to Distribute Dividends for 2025

PharmaEssentia announced that its subsidiary, Pan-Tai Medical Products, has resolved not to issue an… · 2026-05-15

[PharmaEssentia] Announcement of significant resolutions from the 2026 annual general meeting (acting by the Board) of major subsidiary FanTai Medical Products Co., Ltd.

PharmaEssentia's major subsidiary, FanTai Medical Products Co., Ltd., held its 2026 annual general m… · 2026-05-15

[PharmaEssentia] Announcement of significant resolutions from the 2026 annual general meeting (acting by the Board) of major subsidiary FanTai Medical Products Co., Ltd.

PharmaEssentia's major subsidiary, FanTai Medical Products Co., Ltd., held its 2026 annual general m… · 2026-05-15

PharmaEngine, Inc.: Company Invited to Participate in Investor Conference Hosted by SinoPac Securities

PharmaEngine, Inc. has been invited to participate in an investor conference hosted by SinoPac Secur… · 2026-05-14

PharmaEngine, Inc.: Company Invited to Participate in Investor Conference Hosted by SinoPac Securities

PharmaEngine, Inc. has been invited to participate in an investor conference hosted by SinoPac Secur… · 2026-05-14

[PharmaEssentia] Announcement of the Board of Directors' Approval of the Q1 2026 Consolidated Financial Report

PharmaEssentia's Board of Directors approved its Q1 2026 consolidated financial report (January 1 to… · 2026-05-13

[PharmaEssentia] Announcement of the Board of Directors' Approval of the Q1 2026 Consolidated Financial Report

PharmaEssentia's Board of Directors approved its Q1 2026 consolidated financial report (January 1 to… · 2026-05-13

PharmaEssentia: Board of Directors Resolves to Repurchase and Cancel Restricted Stock Units for Employees and Sets Capital Reduction Record Date

PharmaEssentia announced that its Board of Directors resolved to repurchase and cancel restricted st… · 2026-05-13

PharmaEssentia: Board of Directors Resolves to Repurchase and Cancel Restricted Stock Units for Employees and Sets Capital Reduction Record Date

PharmaEssentia announced that its Board of Directors resolved to repurchase and cancel restricted st… · 2026-05-13

【PharmaEssentia】Company's New Drug BESREMi (Ropeginterferon alfa-2b) Receives Approval Letter from Ministry of Health and Welfare for Use in Essential Thrombocythemia (ET)

PharmaEssentia's new drug BESREMi has received approval from Taiwan's Ministry of Health and Welfare… · 2026-05-12

YaoHua Pharma Media Report Clarification

Company had no comment; negotiations entered a later stage, it remains open to solutions. · 2026-05-12

【PharmaEssentia】Company's New Drug BESREMi (Ropeginterferon alfa-2b) Receives Approval Letter from Ministry of Health and Welfare for Use in Essential Thrombocythemia (ET)

PharmaEssentia's new drug BESREMi has received approval from Taiwan's Ministry of Health and Welfare… · 2026-05-12

PharmaEssentia: Announcement of Board Meeting for Q1 2026 Consolidated Financial Report Scheduled for May 13, 2026

PharmaEssentia announced that its board meeting for the Q1 2026 consolidated financial report is sch… · 2026-05-05

PharmaEssentia: Announcement of Board Meeting for Q1 2026 Consolidated Financial Report Scheduled for May 13, 2026

PharmaEssentia announced that its board meeting for the Q1 2026 consolidated financial report is sch… · 2026-05-05

[PharmaEssentia] May 2026 Revenue Reaches NT$2.458 Billion (Up +108.5% YoY)

Biotech company PharmaEssentia (Code: 6446) announced its May 2026 monthly revenue of NT$2.458 billi… · 2026-05-01

Presolver Pharmaceuticals Announces Appeal to German Federal Supreme Court Regarding Arbitration Case

Presolver Pharmaceuticals announced its appeal to the German Federal Supreme Court concerning an arb… · 2026-04-30

Presolver Pharmaceuticals Announces Appeal to German Federal Supreme Court Regarding Arbitration Case

Presolver Pharmaceuticals announced its appeal to the German Federal Supreme Court concerning an arb… · 2026-04-30

[PharmaEssentia] Update on Progress of the Petition to Set Aside Arbitration Award

PharmaEssentia announced that the Higher Regional Court of Frankfurt dismissed its petition to set a… · 2026-04-24

[PharmaEssentia] Update on Progress of the Petition to Set Aside Arbitration Award

PharmaEssentia announced that the Higher Regional Court of Frankfurt dismissed its petition to set a… · 2026-04-24

[PharmaEssentia] Announcement that the Company's Taichung Plant has received GMP certification from the Drug Administration of Vietnam (DAV)

PharmaEssentia's Taichung plant achieved GMP certification from Vietnam's DAV, clearing a key hurdle… · 2026-04-22

[PharmaEssentia] Announcement that the Company's Taichung Plant has received GMP certification from the Drug Administration of Vietnam (DAV)

PharmaEssentia's Taichung plant achieved GMP certification from Vietnam's DAV, clearing a key hurdle… · 2026-04-22

PharmaEssentia: Announcement of the Company's Board of Directors' Resolution to Acquire 100% Equity of Forus Therapeutics Inc.

PharmaEssentia's board of directors resolved on April 9, 2026, to acquire 100% of Forus Therapeutics… · 2026-04-09

PharmaEssentia: Announcement of the Company's Board of Directors' Resolution to Acquire 100% Equity of Forus Therapeutics Inc.

PharmaEssentia's board of directors resolved on April 9, 2026, to acquire 100% of Forus Therapeutics… · 2026-04-09

PharmaEssentia: Announcement of the Company's Board of Directors' Resolution to Invest and Establish a Subsidiary, PharmaEssentia Puerto Rico LLC, in Puerto Rico, USA (Updated Total Transaction Amount)

PharmaEssentia's board of directors resolved on April 9, 2026, to reduce the total investment for it… · 2026-04-09

PharmaEssentia: Announcement of the Company's Board of Directors' Resolution to Invest and Establish a Second Subsidiary in Puerto Rico, USA

PharmaEssentia's board of directors resolved on April 9, 2026, to establish a second subsidiary, Pha… · 2026-04-09

PharmaEssentia: Announcement of the Company's Board of Directors' Resolution to Invest and Establish a Second Subsidiary in Puerto Rico, USA

PharmaEssentia's board of directors resolved on April 9, 2026, to establish a second subsidiary, Pha… · 2026-04-09

PharmaEssentia: Announcement of the Company's Board of Directors' Resolution to Acquire 100% Equity of Forus Therapeutics Inc.

PharmaEssentia's board of directors resolved on April 9, 2026, to acquire 100% of Forus Therapeutics… · 2026-04-09

PharmaEssentia: Announcement of the Company's Board of Directors' Resolution to Invest and Establish a Subsidiary, PharmaEssentia Puerto Rico LLC, in Puerto Rico, USA (Updated Total Transaction Amount)

PharmaEssentia's board of directors resolved on April 9, 2026, to reduce the total investment for it… · 2026-04-09

PharmaEssentia: Announcement of the Company's Board of Directors' Resolution to Invest and Establish a Second Subsidiary in Puerto Rico, USA

PharmaEssentia's board of directors resolved on April 9, 2026, to establish a second subsidiary, Pha… · 2026-04-09

PharmaEssentia: Announcement of the Company's Board of Directors' Resolution to Invest and Establish a Subsidiary, PharmaEssentia Puerto Rico LLC, in Puerto Rico, USA (Updated Total Transaction Amount)

PharmaEssentia's board of directors resolved on April 9, 2026, to reduce the total investment for it… · 2026-04-09

PharmaEssentia Reports April 2026 Revenue of NT$2.064 Billion (Up 68.3% YoY)

PharmaEssentia (6446) announced its revenue for April 2026, reaching NT$2.064 billion, a significant… · 2026-04-01

YaoHua Yao Reports April 2026 Revenue of NT$2.064 Billion, Up 68.3% Year-over-Year

YaoHua Yao (stock code: 6446) announced its revenue for April 2026 reached NT$2.064 billion (NT$2,06… · 2026-04-01

PharmaEssentia: March 2026 Monthly Revenue NT$1.94 Billion (YoY +64.4%)

PharmaEssentia announced its March 2026 monthly revenue reached NT$1.94 billion, marking a substanti… · 2026-03-01

PharmaEssentia: March 2026 Monthly Revenue NT$1.94 Billion (YoY +64.4%)

PharmaEssentia announced its March 2026 monthly revenue reached NT$1.94 billion, marking a substanti… · 2026-03-01

【PharmaEssentia】February 2026 Revenue Reaches 1.60 Billion (YoY +56.7%)

PharmaEssentia, a new drug development company, announced that its revenue for February 2026 reached… · 2026-02-01

【PharmaEssentia】February 2026 Revenue Reaches 1.60 Billion (YoY +56.7%)

PharmaEssentia, a new drug development company, announced that its revenue for February 2026 reached… · 2026-02-01